

Application No. (if known): 09/621,574

Attorney Docket No.: 58071-CON/RCE (47126)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV654383525US in an envelope addressed to:

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 23, 2005
Date



Signature

Lakeisha Bryant

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement, including duplicate copy thereof;
Form PTO/SB/08 (2 pages);
Copy of IDS Citations (46 References).



Docket No.: 58071-CON/RCE (47126)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gregor Cevc

Application No.: 09/621,574 - Conf. No.: 5661 Art Unit: 1615

Filed: July 21, 2000

Examiner: G. S. Kishore

For: PREPARATION FOR THE APPLICATION OF AGENTS IN MINI-DROPLETS

INFORMATION DISCLOSURE STATEMENT (IDS)

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.


A copy of each reference on the PTO/SB/08 is attached.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 58071CON(47126). A duplicate copy of this paper is enclosed.

Dated: May 23, 2005

EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444

Respectfully submitted,

By 
Lisa Swiszczy Hazzard
Registration No.: 44,368
Attorney For Applicant



JC145

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/621,574-Conf. #5661
				Filing Date	July 21, 2000
				First Named Inventor	Gregor Cevc
				Art Unit	1615
				Examiner Name	G. S. Kishore
Sheet	1	of	2	Attorney Docket Number	58071CON(47126)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,238,613	08-24-1993	Anderson	
	AB	US-5,958,379	09-28-1999	Regenold, et al.	
	AC	US-6,562,370-B2	05-13-2003	Luo, et al.	
	AD	US-6,582,724-B2	06-24-2003	Hsu, et al.	
	AE	US-6,586,000-B2	07-01-2003	Luo, et al.	
	AF	US-6,645,520-B2	11-11-2003	Hsu, et al.	
	AG	US-6,835,392-B2	12-28-2004	Hsu, et al.	
	AH	US-2002/0048596-A1	04-25-2002	Cevc	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	CA-2 067 754	03-05-1992	IDEA AG		
	BBC	EP-0 382 716	01-28-1988	WARNER-LAMBERT CO.		
	BC	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
	BD	EP-0 995 435	04-26-2000	SENJU PHARMA. CO., LTD.		
	BE	WO-92/22292	12-23-1992	SCHWARZ PHARMA		
	BF	WO-94/26257	11-24-1994	LOHMANN THERAPIE- SYSTEME GMBH & CO.		
	BG	WO-96/29999	10-03-1996	HEXAL AG		
	BH	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
	BI	WO-98/17255	04-30-1998	Cevc		
	BJ	WO-99/22703	05-14-1999	LURIDENT, LTD.		
	BK	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
	BL	WO-00/25822	05-11-2000	John C. Grasela, et al		
	BM	WO-00/38653	07-06-2000	IDEA INNOVATIVE DERMALE APPLIKATIONEN GMBH		
	BN	WO-00/44350	08-03-2000	IDEA AG		
	BO	WO-00/50007	08-31-2000	LIPOCINE, INC.		
	BP	WO-01/01963	01-11-2001	IDEA AG		
	BQ	WO-01/12155	02-22-2001	LIPOCINE, INC.		
	BR	WO-02/07767	01-31-2002	ALCON UNIVERSAL LTD.		
	BS	HU 9903363	03-28-2000	Cevc	English abstract corresponds to US20020048596	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/621,574-Conf. #5661
				Filing Date	July 21, 2000
				First Named Inventor	Gregor Cevc
				Art Unit	1615
				Examiner Name	G. S. Kishore
Sheet	2	of	2	Attorney Docket Number	58071CON(47126)

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BT	HU-0104424	03-28-2002	IDEA AG	English abstract corresponds to WO0038653	
	BU	HU-0105400	05-29-2002	IDEA AG	English abstract corresponds to WO0044350	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	CA	Prof. Dr. K-U Benner, "Der Korper des Menschen", page 49 (1995).				
	CB	SERVA Feinbiochemica, Katalog, pages 201-202 (1986/1987).				
	CC	FLUKA Chemica-BioChemica, Katalog 16, pages 204, 830 (1988/1989).				
	CD	J. Roeding, "Liposomen und Niosomen in Pharmazie und Kosmetik", Kurs 502 of APV, (May 14-16, 1990).				
	CE	Louis F. Fieser, Mary Fieser, "Organische Chemie", page 1250 (1968).				
	CF	Hans Schreier, "Liposomen - ein neuartiger Arzneistofftrager", <i>Pharmazie in unserer Zeit</i> , pages 97-108 (1982).				
	CG	D. Lichtenberg, "Solubilization of Phospholipids by Detergents Structural and Kinetic Aspects", <i>Biochimica et Biophysica Acta</i> , pages 285 - 304 (1983).				
	CH	Reviews on Biomembranes, <i>Biochimica et Biophysica Acta</i> , Vol. 415 No. 1, pages 29-79 (1975).				
	CI	M. L. Jackson, et al., Solubilization of Phosphatidylcholine Bilayers by Octyl Glucoside, <i>Biochemistry</i> , Vol. 21, pages 4576-4582 (1982).				
	CJ	P. K. Vinson, et al., "Vesicle-micelle transition of phosphatidylcholine and octyl glucoside elucidated by cryo-transmission electron microscopy", <i>Biophysical Journal</i> , Vol 56, pages 669-681 (1989).				
	CK	K. Edwards, et al., Effects of Triton X-100 on Sonicated Lecithin Vesicles, <i>Langmuir</i> , Vol. 5, pages 473-478 (1989).				
	CL	A. Brendzel, et al., Effects of Lipid-Soluble substances on the Thermotropic Properties of Liposome Filtration", <i>Biochimica et Biophysica Acta</i> , Vol. 601, pages 260 - 270 (1980).				
	CM	C. Beyer, "Mikroemulsionen", <i>Pharmazie in unserer Zeit</i> , pages 55-60 (1983).				
	CN	J. Lasch, et al., " Interactions of external lipids (lipid vesicles) with the skin", <i>Journal of Liposome Research</i> , Vol. 5, No. 3, pages 543-569 (1995).				
	CO	M. Berger, "Oral Insulin 1922-1992: The History of Continuous Ambition and Failure".				
	CP	G. Cevc, et al., "The skin: a pathway for systemic treatment with patches and lipid-base agent carriers", <i>Adv. Drug Delivery Reviews</i> , Vol. 18, pages 349-378 (1996).				
	CQ	G. Cevc, et al., "Transfersomes-mediated transepidermal delivery improves the regiospecificity and biological activity of corticosteroids in vivo," <i>Journal of Controlled Releases</i> , Vol. 45, No. 37, pages 211-226 (April 1997).				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--